Last reviewed · How we verify
anidulafungin and voriconazole
Anidulafungin inhibits fungal cell wall synthesis by targeting β-1,3-glucan synthase, while voriconazole inhibits fungal cytochrome P450-dependent sterol synthesis, together providing broad-spectrum antifungal coverage.
Anidulafungin inhibits fungal cell wall synthesis by targeting β-1,3-glucan synthase, while voriconazole inhibits fungal cytochrome P450-dependent sterol synthesis, together providing broad-spectrum antifungal coverage. Used for Invasive candidiasis, Invasive aspergillosis, Other serious fungal infections in immunocompromised patients.
At a glance
| Generic name | anidulafungin and voriconazole |
|---|---|
| Sponsor | Pfizer |
| Drug class | Echinocandin and triazole antifungal combination |
| Target | β-1,3-glucan synthase (anidulafungin); fungal CYP51/lanosterol 14α-demethylase (voriconazole) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Anidulafungin is an echinocandin that disrupts the structural integrity of the fungal cell wall by inhibiting β-1,3-glucan synthase, leading to cell lysis and death. Voriconazole is a triazole that blocks ergosterol synthesis by inhibiting fungal CYP51, disrupting cell membrane function. This combination targets two distinct mechanisms of fungal cell integrity, providing synergistic activity against a wide range of fungal pathogens.
Approved indications
- Invasive candidiasis
- Invasive aspergillosis
- Other serious fungal infections in immunocompromised patients
Common side effects
- Elevated liver enzymes (ALT/AST)
- Visual disturbances
- Hypokalemia
- Infusion-related reactions
- Headache
- Rash
Key clinical trials
- Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents
- Azole-echinocandin Combination Therapy for Invasive Aspergillosis (PHASE3)
- Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects (PHASE3)
- Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis (PHASE3)
- Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis (PHASE4)
- Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study (PHASE3)
- This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis (PHASE4)
- Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- anidulafungin and voriconazole CI brief — competitive landscape report
- anidulafungin and voriconazole updates RSS · CI watch RSS
- Pfizer portfolio CI